DYNE THERAPEUTICS INC (DYN) Stock Fundamental Analysis

NASDAQ:DYN • US26818M1080

15.25 USD
-0.13 (-0.85%)
At close: Feb 19, 2026
15.31 USD
+0.06 (+0.39%)
After Hours: 2/19/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DYN. DYN was compared to 521 industry peers in the Biotechnology industry. While DYN seems to be doing ok healthwise, there are quite some concerns on its profitability. DYN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year DYN has reported negative net income.
  • DYN had a negative operating cash flow in the past year.
  • DYN had negative earnings in each of the past 5 years.
  • In the past 5 years DYN always reported negative operating cash flow.
DYN Yearly Net Income VS EBIT VS OCF VS FCFDYN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of DYN (-48.88%) is comparable to the rest of the industry.
  • DYN has a Return On Equity of -61.26%. This is in the better half of the industry: DYN outperforms 61.23% of its industry peers.
Industry RankSector Rank
ROA -48.88%
ROE -61.26%
ROIC N/A
ROA(3y)-81.24%
ROA(5y)-59.12%
ROE(3y)-125.15%
ROE(5y)-86.67%
ROIC(3y)N/A
ROIC(5y)N/A
DYN Yearly ROA, ROE, ROICDYN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • DYN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DYN Yearly Profit, Operating, Gross MarginsDYN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • DYN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, DYN has more shares outstanding
  • DYN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DYN Yearly Shares OutstandingDYN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DYN Yearly Total Debt VS Total AssetsDYN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 5.69 indicates that DYN is not in any danger for bankruptcy at the moment.
  • DYN has a Altman-Z score of 5.69. This is in the better half of the industry: DYN outperforms 73.70% of its industry peers.
  • DYN has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
  • DYN's Debt to Equity ratio of 0.14 is on the low side compared to the rest of the industry. DYN is outperformed by 62.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 5.69
ROIC/WACCN/A
WACCN/A
DYN Yearly LT Debt VS Equity VS FCFDYN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 13.47 indicates that DYN has no problem at all paying its short term obligations.
  • DYN's Current ratio of 13.47 is amongst the best of the industry. DYN outperforms 89.64% of its industry peers.
  • A Quick Ratio of 13.47 indicates that DYN has no problem at all paying its short term obligations.
  • DYN has a Quick ratio of 13.47. This is amongst the best in the industry. DYN outperforms 89.83% of its industry peers.
Industry RankSector Rank
Current Ratio 13.47
Quick Ratio 13.47
DYN Yearly Current Assets VS Current LiabilitesDYN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • DYN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.81%.
EPS 1Y (TTM)-2.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.62% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.45%
EPS Next 2Y0.43%
EPS Next 3Y2.97%
EPS Next 5Y16.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DYN Yearly Revenue VS EstimatesDYN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
DYN Yearly EPS VS EstimatesDYN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DYN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DYN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DYN Price Earnings VS Forward Price EarningsDYN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DYN Per share dataDYN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.43%
EPS Next 3Y2.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • DYN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DYNE THERAPEUTICS INC

NASDAQ:DYN (2/19/2026, 8:00:01 PM)

After market: 15.31 +0.06 (+0.39%)

15.25

-0.13 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-26
Inst Owners95.07%
Inst Owner Change6.17%
Ins Owners0.23%
Ins Owner Change-0.07%
Market Cap2.46B
Revenue(TTM)N/A
Net Income(TTM)-423.80M
Analysts84
Price Target41.48 (172%)
Short Float %12.37%
Short Ratio7.69
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.77%
Min EPS beat(2)-0.6%
Max EPS beat(2)10.13%
EPS beat(4)2
Avg EPS beat(4)0.16%
Min EPS beat(4)-18.24%
Max EPS beat(4)10.13%
EPS beat(8)3
Avg EPS beat(8)-5.92%
EPS beat(12)4
Avg EPS beat(12)-7.06%
EPS beat(16)6
Avg EPS beat(16)-4.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.77%
PT rev (3m)17.77%
EPS NQ rev (1m)0.28%
EPS NQ rev (3m)-6.75%
EPS NY rev (1m)0.71%
EPS NY rev (3m)3.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.56
P/tB 3.56
EV/EBITDA N/A
EPS(TTM)-3.66
EYN/A
EPS(NY)-3.32
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS0
BVpS4.28
TBVpS4.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.88%
ROE -61.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-81.24%
ROA(5y)-59.12%
ROE(3y)-125.15%
ROE(5y)-86.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1076.9%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.47
Quick Ratio 13.47
Altman-Z 5.69
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.78%
Cap/Depr(5y)173.23%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.83%
EPS Next Y-6.45%
EPS Next 2Y0.43%
EPS Next 3Y2.97%
EPS Next 5Y16.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28%
EBIT Next 3Y-17.68%
EBIT Next 5YN/A
FCF growth 1Y-116.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.04%
OCF growth 3YN/A
OCF growth 5YN/A

DYNE THERAPEUTICS INC / DYN FAQ

Can you provide the ChartMill fundamental rating for DYNE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to DYN.


Can you provide the valuation status for DYNE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DYNE THERAPEUTICS INC (DYN). This can be considered as Overvalued.


What is the profitability of DYN stock?

DYNE THERAPEUTICS INC (DYN) has a profitability rating of 1 / 10.


What is the financial health of DYNE THERAPEUTICS INC (DYN) stock?

The financial health rating of DYNE THERAPEUTICS INC (DYN) is 5 / 10.


Can you provide the expected EPS growth for DYN stock?

The Earnings per Share (EPS) of DYNE THERAPEUTICS INC (DYN) is expected to decline by -6.45% in the next year.